Our goal is to identify Corporate Supporters that share our mission to find a cure for Niemann-Pick Type C disease through outreach, education, and philanthropy. If you are interested in becoming a Corporate Supporter, please contact Sean Kassen at email@example.com.
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.
They harness the amplification of Heat-Shock Proteins (or HSP’s) in order to develop and commercialize novel therapeutics for serious diseases including lysosomal storage diseases and neuromuscular degenerative diseases.
Orphazyme is developing arimoclomol as a treatment for NPC disease.